Definium Therapeutics, Inc. is trading 5.6% down at $22.23 as the stock undergoes a sharp two-day pullback following last week’s run-up and Friday’s macro-driven selloff in growth names.
- The move appears to reflect continued profit-taking and residual interest rate concerns rather than fresh, company-specific news.
- No new regulatory filings, guidance changes, or analyst calls have been released this morning to account for the downward momentum.